HVTN 137: A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 with TLR Agonist and/or Alum Adjuvants in Healthy, HIV-Uninfected Adults.
HVTN 137: HIV Vaccine Trial for Healthy, HIV Negative Adults, Ages 18-50
Sponsor: National Institute of Allergy and Infectious Diseases NIAID
Enrolling: Male and Female Patients
IRB Number: AAAT4185
U.S. Govt. ID: NCT04177355
Contact: Clinical Research Team: 347-770-2201 / jb2226@cumc.columbia.edu
Additional Study Information: The purpose of the study is to test an experimental HIV vaccine. The study vaccine is made from two parts: a man-made piece of protein that looks like a protein found on the outside of HIV and an adjuvant. An adjuvant is a substance that helps the immune system respond better. The study will see if the protein and two different amounts of the same adjuvant are safe and if people can get them without being too uncomfortable. The study will also test how peoples immune systems respond to the vaccine made with two different amounts of the same adjuvant. This is the first study to give this vaccine to people. Clinic visits will involve physical exams, collection of blood and urine for routine laboratory tests (including pregnancy tests if you can get pregnant), HIV testing at some visits, and collection of blood samples to look at your immune responses to the vaccine. Some visits will involve questionnaires, some of which ask very personal questions. You will get vaccine injections at three visits. About 105 people will take part in this study at multiple sites, and you will be paid up to $1025 for completing the entire study.
This study is closed
Investigator
Magdalena Sobieszczyk, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Are you HIV negative? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Clinical Research Team
jb2226@cumc.columbia.edu
347-770-2201